A 42-year-old woman from Mumbai is found to have HBsAg positive on routine blood donation screening. She is asymptomatic with normal liver function tests. Subsequent testing shows: HBsAg+, anti-HBc+, anti-HBc IgM−, HBeAg−, anti-HBe+, HBV DNA 2000 IU/mL. What is the most appropriate next step in management?

Explanation

## Chronic HBV with Low-Level Viremia: Treatment Decision-Making ### Serological Profile Analysis **Key Point:** This patient has **chronic hepatitis B** (HBsAg+ >6 months, anti-HBc IgM−) with **HBeAg-negative disease** and **low-level viremia** (HBV DNA 2000 IU/mL). The critical next step is to assess **liver fibrosis status** before deciding on treatment eligibility. | Feature | This Patient | Significance | |---------|--------------|-------------| | **HBsAg** | Positive | Chronic infection | | **Anti-HBc IgM** | Negative | NOT acute infection | | **HBeAg** | Negative | HBeAg-negative disease (harder to treat) | | **Anti-HBe** | Positive | Seroconversion occurred | | **HBV DNA** | 2000 IU/mL | Low-level viremia | | **ALT** | Normal | No active hepatitis | ### Treatment Eligibility Criteria for Chronic HBV **High-Yield:** Treatment is indicated if ANY of the following are met: 1. **HBeAg-positive disease:** ALT ≥1× ULN AND HBV DNA ≥10^5 IU/mL 2. **HBeAg-negative disease:** ALT ≥1× ULN AND HBV DNA ≥2000 IU/mL (this patient meets viral load threshold) 3. **Cirrhosis:** Regardless of ALT or HBV DNA (any detectable virus) 4. **Advanced fibrosis (F3):** With HBV DNA ≥2000 IU/mL **Clinical Pearl:** This patient has HBV DNA ≥2000 IU/mL (meets threshold for HBeAg-negative disease), BUT has **normal ALT**. Treatment decisions in HBeAg-negative disease with normal ALT hinge on **fibrosis staging**: - **If F0–F2 (no/mild/moderate fibrosis):** Observe; no treatment needed - **If F3–F4 (advanced fibrosis/cirrhosis):** Treat immediately ### Why Fibrosis Assessment is Critical ```mermaid flowchart TD A["Chronic HBV<br/>HBeAg−, HBV DNA 2000 IU/mL<br/>Normal ALT"]:::outcome --> B["Assess Liver Fibrosis"]:::action B --> C{"Fibrosis Stage?"}:::decision C -->|"F0–F2<br/>(No/mild/moderate)"|D["Observe<br/>Repeat HBV DNA & ALT<br/>every 6–12 months"]:::action C -->|"F3–F4<br/>(Advanced/cirrhosis)"|E["Initiate antiviral therapy"]:::action D --> F["Treat if ALT rises<br/>or HBV DNA increases"]:::outcome E --> G["Monitor for response<br/>& complications"]:::outcome ``` ### Fibrosis Assessment Methods **Non-invasive tools** (preferred first-line): - **FIB-4 score:** `$FIB-4 = \frac{Age \times AST}{Platelet\ count \times \sqrt{ALT}}$` (cutoff >1.30 suggests F≥3) - **APRI score:** `$APRI = \frac{AST/ULN}{Platelet\ count} \times 100$` (cutoff >1.0 suggests F≥3) - **Transient elastography (FibroScan):** Gold standard non-invasive; cutoff >9.6 kPa suggests cirrhosis - **Ultrasound:** Assess for splenomegaly, portal hypertension signs **Mnemonic — FAST (Fibrosis Assessment Steps):** - **F**IB-4 or APRI score first - **A**dvanced imaging (FibroScan) if scores borderline - **S**taging determines treatment decision - **T**reat only if F3–F4 or ALT elevated **Warning:** Do NOT start antivirals in HBeAg-negative disease with normal ALT and low-level viremia without confirming advanced fibrosis. Over-treatment increases drug resistance risk and cost without proven benefit. [cite:Harrison 21e Ch 297; AASLD/IDSA HBV Guidance 2018]